{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:56:28Z","timestamp":1791860188741,"version":"4.3.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["2020\u2013707161"],"award-info":[{"award-number":["2020\u2013707161"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["2020\u2013707161"],"award-info":[{"award-number":["2020\u2013707161"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["2020\u2013707161"],"award-info":[{"award-number":["2020\u2013707161"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["400678"],"award-info":[{"award-number":["400678"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["400678"],"award-info":[{"award-number":["400678"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["400678"],"award-info":[{"award-number":["400678"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Riddell Centre for Cancer Immunotherapy Alberta Cancer Foundation BioCanRx"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01194-3","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:28:53Z","timestamp":1782919733000},"page":"1189-1207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["GPNMB-directed CAR T cell therapy against MiT\/TFE-family fusion-driven solid tumors"],"prefix":"10.1038","volume":"7","author":[{"given":"Franz J.","family":"Zemp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zackariah","family":"Breckenridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2916-0644","authenticated-orcid":false,"given":"Hyojin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6860-6233","authenticated-orcid":false,"given":"Gurveer S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taye L.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Narta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongrui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4876-1385","authenticated-orcid":false,"given":"Yeon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Guignard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna Ayerim","family":"Mandujano-Tinoco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6293-4018","authenticated-orcid":false,"given":"Nicol\u00e1s","family":"Collao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Pyczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristofor K.","family":"Ellestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jada","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jethro","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5404-6176","authenticated-orcid":false,"given":"Cini","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K.","family":"Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3409-4319","authenticated-orcid":false,"given":"Jahanara","family":"Rajwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyel","family":"Evseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-8406","authenticated-orcid":false,"given":"Madison","family":"Turk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Benaoudia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5316-5090","authenticated-orcid":false,"given":"Jonathan","family":"Alex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Naumenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha Thoppey","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobina Kazemi","family":"Mehrabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9926-8188","authenticated-orcid":false,"given":"Harmony A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geneece N. Y.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Gillmor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4292-0839","authenticated-orcid":false,"given":"Ted B.","family":"Verhey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6905-3667","authenticated-orcid":false,"given":"Hayley M.","family":"Todesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Osz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Young","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Bogossian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7803-2059","authenticated-orcid":false,"given":"Saif","family":"Sikdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrbano","family":"Rukunuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek A.","family":"Bismar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y. C.","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7983-3109","authenticated-orcid":false,"given":"W. Marston","family":"Linehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4485-4489","authenticated-orcid":false,"given":"Haley","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2881-1713","authenticated-orcid":false,"given":"Paul M. K.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5016-0753","authenticated-orcid":false,"given":"Livia","family":"Garzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Brodeur-Robb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"DiFrancesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1746-8668","authenticated-orcid":false,"given":"Travis","family":"Ogilvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7259-1247","authenticated-orcid":false,"given":"Robert A.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9083-357X","authenticated-orcid":false,"given":"John","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-3395","authenticated-orcid":false,"given":"Donna L.","family":"Senger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Monument","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-5360","authenticated-orcid":false,"given":"Omar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lou","family":"Baudrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Billon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Biernaskie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Potts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiril","family":"Trpkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-2677","authenticated-orcid":false,"given":"Kevin","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Quizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9798-1551","authenticated-orcid":false,"given":"Jennifer","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem","family":"Henning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Prokopishyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Shafey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8526-562X","authenticated-orcid":false,"given":"A. Sorana","family":"Morrissy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0642-992X","authenticated-orcid":false,"given":"Douglas J.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"1194_CR1","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah, N. N. et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J. Clin. Oncol. 39, 1650\u20131659 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1194_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17175-8","volume":"11","author":"M Hegde","year":"2020","unstructured":"Hegde, M. et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat. Commun. 11, 3549 (2020).","journal-title":"Nat. Commun."},{"key":"1194_CR3","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1194_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1194_CR5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 (2010).","journal-title":"Mol. Ther."},{"key":"1194_CR6","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1194_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1146\/annurev-cancerbio-030518-055710","volume":"3","author":"JA Perry","year":"2019","unstructured":"Perry, J. A., Seong, B. K. A. & Stegmaier, K. Biology and therapy of dominant fusion oncoproteins involving transcription factor and chromatin regulators in sarcomas. Annu. Rev. Cancer Biol. 3, 299\u2013321 (2019).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"1194_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Gr\u00f6bner","year":"2018","unstructured":"Gr\u00f6bner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321\u2013327 (2018).","journal-title":"Nature"},{"key":"1194_CR9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ajur.2019.04.003","volume":"6","author":"L Xie","year":"2019","unstructured":"Xie, L., Zhang, Y. & Wu, C.-L. Microphthalmia family of transcription factors associated renal cell carcinoma. Asian J. Urol. 6, 312\u2013320 (2019).","journal-title":"Asian J. Urol."},{"key":"1194_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrurol.2014.162","volume":"11","author":"EC Kauffman","year":"2014","unstructured":"Kauffman, E. C. et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat. Rev. Urol. 11, 465\u2013475 (2014).","journal-title":"Nat. Rev. Urol."},{"key":"1194_CR11","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/hmg\/5.9.1333","volume":"5","author":"SK Sidhar","year":"1996","unstructured":"Sidhar, S. K. et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum. Mol. Genet. 5, 1333\u20131338 (1996).","journal-title":"Hum. Mol. Genet."},{"key":"1194_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner, J. E., Hnisz, D. & Young, R. A. Transcriptional addiction in cancer. Cell 168, 629\u2013643 (2017).","journal-title":"Cell"},{"key":"1194_CR13","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1038\/s41388-022-02443-2","volume":"41","author":"A-M Lazaratos","year":"2022","unstructured":"Lazaratos, A.-M., Annis, M. G. & Siegel, P. M. GPNMB: a potent inducer of immunosuppression in cancer. Oncogene 41, 4573\u20134590 (2022).","journal-title":"Oncogene"},{"key":"1194_CR14","doi-asserted-by":"publisher","first-page":"674739","DOI":"10.3389\/fimmu.2021.674739","volume":"12","author":"M Saade","year":"2021","unstructured":"Saade, M., Araujo de Souza, G., Scavone, C. & Kinoshita, P. F. The role of GPNMB in inflammation. Front. Immunol. 12, 674739 (2021).","journal-title":"Front. Immunol."},{"key":"1194_CR15","doi-asserted-by":"publisher","first-page":"e15793","DOI":"10.1371\/journal.pone.0015793","volume":"5","author":"S-B Hong","year":"2010","unstructured":"Hong, S.-B. et al. Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. PLoS ONE 5, e15793 (2010).","journal-title":"PLoS ONE"},{"key":"1194_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13046-023-02667-4","volume":"42","author":"M Lang","year":"2023","unstructured":"Lang, M. et al. High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma. J. Exp. Clin. Cancer Res. 42, 99 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1194_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/path.4158","volume":"229","author":"R Kobos","year":"2013","unstructured":"Kobos, R. et al. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1\u2013TFE3 fusion oncoprotein. J. Pathol. 229, 743\u2013754 (2013).","journal-title":"J. Pathol."},{"key":"1194_CR18","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1158\/1541-7786.MCR-18-1235","volume":"17","author":"M Baba","year":"2019","unstructured":"Baba, M. et al. TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease. Mol. Cancer Res. 17, 1613\u20131626 (2019).","journal-title":"Mol. Cancer Res."},{"key":"1194_CR19","doi-asserted-by":"publisher","first-page":"6675260","DOI":"10.1155\/2021\/6675260","volume":"2021","author":"C-J Lee","year":"2021","unstructured":"Lee, C.-J. et al. Establishment of an academic tissue microarray platform as a tool for soft tissue sarcoma research. Sarcoma 2021, 6675260 (2021).","journal-title":"Sarcoma"},{"key":"1194_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/path.5875","volume":"257","author":"DC Salles","year":"2022","unstructured":"Salles, D. C. et al. GPNMB expression identifies TSC1\/2\/mTOR-associated and MiT family translocation-driven renal neoplasms. J. Pathol. 257, 158\u2013171 (2022).","journal-title":"J. Pathol."},{"key":"1194_CR21","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-05-2018","volume":"12","author":"KF Tse","year":"2006","unstructured":"Tse, K. F. et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin. Cancer Res. 12, 1373\u20131382 (2006).","journal-title":"Clin. Cancer Res."},{"key":"1194_CR22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.immuni.2020.07.011","volume":"53","author":"W Li","year":"2020","unstructured":"Li, W. et al. Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy. Immunity 53, 456\u2013470 (2020).","journal-title":"Immunity"},{"key":"1194_CR23","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1084\/jem.20060710","volume":"203","author":"P Mrass","year":"2006","unstructured":"Mrass, P. et al. Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J. Exp. Med. 203, 2749\u20132761 (2006).","journal-title":"J. Exp. Med."},{"key":"1194_CR24","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3389\/fimmu.2020.01514","volume":"11","author":"D Lau","year":"2020","unstructured":"Lau, D. et al. Intravital imaging of adoptive T-cell morphology, mobility and trafficking following immune checkpoint inhibition in a mouse melanoma model. Front. Immunol. 11, 1514 (2020).","journal-title":"Front. Immunol."},{"key":"1194_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jamaoncol.2018.4490","volume":"5","author":"L Paoluzzi","year":"2019","unstructured":"Paoluzzi, L. & Maki, R. G. Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma. JAMA Oncol. 5, 254\u2013260 (2019).","journal-title":"JAMA Oncol."},{"key":"1194_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ejca.2019.08.015","volume":"121","author":"LM Kopp","year":"2019","unstructured":"Kopp, L. M. et al. Phase II trial of the glycoprotein non-metastatic B-targeted antibody\u2013drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: a report from the Children\u2019s Oncology Group. Eur. J. Cancer 121, 177\u2013183 (2019).","journal-title":"Eur. J. Cancer"},{"key":"1194_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00244-6","volume":"7","author":"LT Vahdat","year":"2021","unstructured":"Vahdat, L. T. et al. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (\u2018METRIC\u2019): a randomized multicenter study. NPJ Breast Cancer 7, 57 (2021).","journal-title":"NPJ Breast Cancer"},{"key":"1194_CR28","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1200\/JCO.2014.56.2959","volume":"33","author":"DA Yardley","year":"2015","unstructured":"Yardley, D. A. et al. EMERGE: a randomized phase II study of the antibody\u2013drug conjugate glembatumumab vedotin in advanced glycoprotein NMB\u2013expressing breast cancer. J. Clin. Oncol. 33, 1609\u20131619 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1194_CR29","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1200\/JCO.2013.52.5683","volume":"32","author":"J Bendell","year":"2014","unstructured":"Bendell, J. et al. Phase I\/II study of the antibody\u2013drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 32, 3619\u20133625 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1194_CR30","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3390\/cancers12082270","volume":"12","author":"M Hasanov","year":"2020","unstructured":"Hasanov, M. et al. A phase II study of glembatumumab vedotin for metastatic uveal melanoma. Cancers 12, 2270 (2020).","journal-title":"Cancers"},{"key":"1194_CR31","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1200\/JCO.2013.54.8115","volume":"32","author":"PA Ott","year":"2014","unstructured":"Ott, P. A. et al. Phase I\/II study of the antibody\u2013drug conjugate glembatumumab vedotin in patients with advanced melanoma. J. Clin. Oncol. 32, 3659\u20133666 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1194_CR32","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/cncr.31892","volume":"125","author":"PA Ott","year":"2019","unstructured":"Ott, P. A. et al. A phase 2 study of glembatumumab vedotin, an antibody\u2013drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer 125, 1113\u20131123 (2019).","journal-title":"Cancer"},{"key":"1194_CR33","unstructured":"Savage, N. et al. Dual tumor-myeloid targeting of glioblastoma with GPNMB CAR-T cells. Nature (in the press)."},{"key":"1194_CR34","doi-asserted-by":"publisher","first-page":"e0278390","DOI":"10.1371\/journal.pone.0278390","volume":"18","author":"PKF Christensen","year":"2023","unstructured":"Christensen, P. K. F. et al. Sustaining the T-cell activity in xenografted psoriasis skin. PLoS ONE 18, e0278390 (2023).","journal-title":"PLoS ONE"},{"key":"1194_CR35","doi-asserted-by":"publisher","first-page":"e2023134","DOI":"10.5826\/dpc.1302a134","volume":"13","author":"S Emre","year":"2023","unstructured":"Emre, S. et al. Investigation of the PD-1\/PD-L1 expression in the lesional skins of patients with psoriasis. Dermatol. Pract. Concept. 13, e2023134 (2023).","journal-title":"Dermatol. Pract. Concept."},{"key":"1194_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1194_CR37","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41586-024-08411-y","volume":"638","author":"G Heimberg","year":"2024","unstructured":"Heimberg, G. et al. A cell atlas foundation model for scalable search of similar human cells. Nature 638, 1085\u20131094 (2024).","journal-title":"Nature"},{"key":"1194_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47\u201366 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1194_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41568-024-00761-z","volume":"25","author":"D Hanahan","year":"2024","unstructured":"Hanahan, D., Michielin, O. & Pittet, M. J. Convergent inducers and effectors of T cell paralysis in the tumour microenvironment. Nat. Rev. Cancer 25, 41\u201358 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"1194_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-024-03407-3","volume":"25","author":"VT Manoharan","year":"2024","unstructured":"Manoharan, V. T. et al. Spatiotemporal modeling reveals high-resolution invasion states in glioblastoma. Genome Biol. 25, 264 (2024).","journal-title":"Genome Biol."},{"key":"1194_CR41","doi-asserted-by":"publisher","first-page":"e163128","DOI":"10.1172\/JCI163128","volume":"133","author":"JM Konen","year":"2023","unstructured":"Konen, J. M. et al. Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer. J. Clin. Invest. 133, e163128 (2023).","journal-title":"J. Clin. Invest."},{"key":"1194_CR42","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2303383","volume":"389","author":"AP Chen","year":"2023","unstructured":"Chen, A. P. et al. Atezolizumab for advanced alveolar soft part sarcoma. N. Engl. J. Med. 389, 911\u2013921 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1194_CR43","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho, B. C. et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 23, 781\u2013792 (2022).","journal-title":"Lancet Oncol."},{"key":"1194_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61931-1","volume":"10","author":"KB Biswas","year":"2020","unstructured":"Biswas, K. B. et al. GPNMB is expressed in human epidermal keratinocytes but disappears in the vitiligo lesional skin. Sci. Rep. 10, 4930 (2020).","journal-title":"Sci. Rep."},{"key":"1194_CR45","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop, M. R. et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N. Engl. J. Med. 386, 629\u2013639 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1194_CR46","doi-asserted-by":"publisher","first-page":"629722","DOI":"10.3389\/fimmu.2020.629722","volume":"11","author":"SI Kim","year":"2021","unstructured":"Kim, S. I., Cassella, C. R. & Byrne, K. T. Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes. Front. Immunol. 11, 629722 (2021).","journal-title":"Front. Immunol."},{"key":"1194_CR47","doi-asserted-by":"publisher","first-page":"e319_70094","DOI":"10.1002\/hon.70094_319","volume":"43","author":"WS Kim","year":"2025","unstructured":"Kim, W. S. et al. Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed\/refractory large B-cell lymphoma. Hematol. Oncol. 43, e319_70094 (2025).","journal-title":"Hematol. Oncol."},{"key":"1194_CR48","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1200\/JCO.2024.42.16_suppl.1089","volume":"42","author":"Y Lin","year":"2024","unstructured":"Lin, Y. et al. Phase I clinical trial of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of advanced breast cancer. J. Clin. Oncol. 42, 1089\u20131089 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1194_CR49","doi-asserted-by":"publisher","first-page":"e008429","DOI":"10.1136\/jitc-2023-008429","volume":"12","author":"W Ouyang","year":"2024","unstructured":"Ouyang, W. et al. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion. J. Immunother. Cancer 12, e008429 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1194_CR50","doi-asserted-by":"publisher","first-page":"ddaf173","DOI":"10.1093\/hmg\/ddaf173","volume":"35","author":"CJ Ricketts","year":"2026","unstructured":"Ricketts, C. J. et al. Tuberous sclerosis complex-associated renal cell carcinoma, an underappreciated form of familial renal cancer, is characterized by activation of the TFEB\/TFE3 pathway. Hum. Mol. Genet. 35, ddaf173 (2026).","journal-title":"Hum. Mol. Genet."},{"key":"1194_CR51","doi-asserted-by":"publisher","first-page":"e16877","DOI":"10.15252\/emmm.202216877","volume":"15","author":"C Di Malta","year":"2023","unstructured":"Di Malta, C. et al. TFEB and TFE3 drive kidney cystogenesis and tumorigenesis. EMBO Mol. Med. 15, e16877 (2023).","journal-title":"EMBO Mol. Med."},{"key":"1194_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91588-3","volume":"11","author":"Y-H Huang","year":"2021","unstructured":"Huang, Y.-H. et al. Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer. Sci. Rep. 11, 12171 (2021).","journal-title":"Sci. Rep."},{"key":"1194_CR53","doi-asserted-by":"publisher","first-page":"104239","DOI":"10.1016\/j.ebiom.2022.104239","volume":"83","author":"A Xiong","year":"2022","unstructured":"Xiong, A., Zhang, J., Chen, Y., Zhang, Y. & Yang, F. Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM. EBioMedicine 83, 104239 (2022).","journal-title":"EBioMedicine"},{"key":"1194_CR54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40478-024-01754-7","volume":"12","author":"F Yalcin","year":"2024","unstructured":"Yalcin, F. et al. Tumor associated microglia\/macrophages utilize GPNMB to promote tumor growth and alter immune cell infiltration in glioma. Acta Neuropathol. Commun. 12, 50 (2024).","journal-title":"Acta Neuropathol. Commun."},{"key":"1194_CR55","doi-asserted-by":"publisher","first-page":"e9394","DOI":"10.7717\/peerj.9394","volume":"8","author":"LH Stockwin","year":"2020","unstructured":"Stockwin, L. H. Alveolar soft-part sarcoma (ASPS) resembles a mesenchymal stromal progenitor: evidence from meta-analysis of transcriptomic data. PeerJ 8, e9394 (2020).","journal-title":"PeerJ"},{"key":"1194_CR56","doi-asserted-by":"publisher","first-page":"e0121314","DOI":"10.1371\/journal.pone.0121314","volume":"10","author":"D Bausch-Fluck","year":"2015","unstructured":"Bausch-Fluck, D. et al. A mass spectrometric-derived cell surface protein atlas. PLoS ONE 10, e0121314 (2015).","journal-title":"PLoS ONE"},{"key":"1194_CR57","doi-asserted-by":"publisher","first-page":"bau012","DOI":"10.1093\/database\/bau012","volume":"2014","author":"JX Binder","year":"2014","unstructured":"Binder, J. X. et al. COMPARTMENTS: unification and visualization of protein subcellular localization evidence. Database 2014, bau012 (2014).","journal-title":"Database"},{"key":"1194_CR58","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"1194_CR59","doi-asserted-by":"publisher","first-page":"E10988","DOI":"10.1073\/pnas.1808790115","volume":"115","author":"D Bausch-Fluck","year":"2018","unstructured":"Bausch-Fluck, D. et al. The in silico human surfaceome. Proc. Natl Acad. Sci. USA 115, E10988\u2013E10997 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1194_CR60","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1093\/bioinformatics\/btaa092","volume":"36","author":"M Waas","year":"2020","unstructured":"Waas, M. et al. SurfaceGenie: a web-based application for prioritizing cell-type-specific marker candidates. Bioinformatics 36, 3447\u20133456 (2020).","journal-title":"Bioinformatics"},{"key":"1194_CR61","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1158\/1078-0432.CCR-13-2090","volume":"20","author":"S Selvarajah","year":"2014","unstructured":"Selvarajah, S. et al. High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma. Clin. Cancer Res. 20, 1521\u20131530 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1194_CR62","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1200\/JCO.2012.47.4288","volume":"31","author":"S Kummar","year":"2013","unstructured":"Kummar, S. et al. Cediranib for metastatic alveolar soft part sarcoma. J. Clin. Oncol. 31, 2296\u20132302 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1194_CR63","doi-asserted-by":"publisher","first-page":"110047","DOI":"10.1016\/j.celrep.2021.110047","volume":"37","author":"AS Brohl","year":"2021","unstructured":"Brohl, A. S. et al. Immuno-transcriptomic profiling of extracranial pediatric solid malignancies. Cell Rep. 37, 110047 (2021).","journal-title":"Cell Rep."},{"key":"1194_CR64","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nature13302","volume":"509","author":"M-S Kim","year":"2014","unstructured":"Kim, M.-S. et al. A draft map of the human proteome. Nature 509, 575\u2013581 (2014).","journal-title":"Nature"},{"key":"1194_CR65","doi-asserted-by":"publisher","first-page":"e8503","DOI":"10.15252\/msb.20188503","volume":"15","author":"D Wang","year":"2019","unstructured":"Wang, D. et al. A deep proteome and transcriptome abundance atlas of 29 healthy human tissues. Mol. Syst. Biol. 15, e8503 (2019).","journal-title":"Mol. Syst. Biol."},{"key":"1194_CR66","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/ijc.25645","volume":"129","author":"C Kuan","year":"2011","unstructured":"Kuan, C. et al. Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. Int. J. Cancer 129, 111\u2013121 (2011).","journal-title":"Int. J. Cancer"},{"key":"1194_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-1-4939-3801-8_11","volume":"1458","author":"JA Hammill","year":"2016","unstructured":"Hammill, J. A., Afsahi, A., Bramson, J. L. & Helsen, C. W. Viral engineering of chimeric antigen receptor expression on murine and human T lymphocytes. Methods Mol. Biol. 1458, 137\u2013157 (2016).","journal-title":"Methods Mol. Biol."},{"key":"1194_CR68","first-page":"55080","volume":"122","author":"KA Murphy","year":"2017","unstructured":"Murphy, K. A., James, B. R., Wilber, A. & Griffith, T. S. A syngeneic mouse model of metastatic renal cell carcinoma for quantitative and longitudinal assessment of preclinical therapies. J. Vis. Exp. 122, 55080 (2017).","journal-title":"J. Vis. Exp."},{"key":"1194_CR69","doi-asserted-by":"publisher","unstructured":"Langley, J. et al. Base editing protocol: disruption of PDCD1, TIGIT, and TRAC loci in primary T cells using adenine and cytosine base editors delivered as IVT mRNA. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.rm7vzwmx8vx1\/v1 (2026).","DOI":"10.17504\/protocols.io.rm7vzwmx8vx1\/v1"},{"key":"1194_CR70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/cells7070069","volume":"7","author":"M Turk","year":"2018","unstructured":"Turk, M., Naumenko, V., Mahoney, D. J. & Jenne, C. N. Tracking cell recruitment and behavior within the tumor microenvironment using advanced intravital imaging approaches. Cells 7, 69 (2018).","journal-title":"Cells"},{"key":"1194_CR71","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nri2638","volume":"9","author":"JB Beltman","year":"2009","unstructured":"Beltman, J. B., Mar\u00e9e, A. F. M. & de Boer, R. J. Analysing immune cell migration. Nat. Rev. Immunol. 9, 789\u2013798 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"1194_CR72","doi-asserted-by":"publisher","unstructured":"Zemp, F., Liu, H. & Mahoney, D. IHC protocol: immunohistochemical staining of paraffin-embedded tissue sections for GPNMB, TFE3, PD-L1, CD3, MYC, and Ki67. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.ewov1ejnpgr2\/v1 (2026).","DOI":"10.17504\/protocols.io.ewov1ejnpgr2\/v1"},{"key":"1194_CR73","doi-asserted-by":"publisher","unstructured":"Zemp, F., Guignard, L. & Mahoney, D. Immunofluorescence (IF) protocol: detection of GPNMB and TFE3 in cultured ASPS cell lines. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.x54v99eyqv3e\/v1 (2026).","DOI":"10.17504\/protocols.io.x54v99eyqv3e\/v1"},{"key":"1194_CR74","doi-asserted-by":"publisher","unstructured":"Zemp, F., Liu, H. & Mahoney, D. OPAL multiplex immunofluorescence (mIF) protocol: 4-plex staining for CD155, GPNMB, CD31, and CD112. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.eq2lymznmlx9\/v1 (2026).","DOI":"10.17504\/protocols.io.eq2lymznmlx9\/v1"},{"key":"1194_CR75","doi-asserted-by":"publisher","first-page":"1074740","DOI":"10.3389\/fimmu.2022.1074740","volume":"13","author":"N Kekre","year":"2022","unstructured":"Kekre, N. et al. CLIC-01: manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. Front. Immunol. 13, 1074740 (2022).","journal-title":"Front. Immunol."},{"key":"1194_CR76","doi-asserted-by":"publisher","unstructured":"Todesco, H., Potts, K. & Mahoney, D. ddPCR protocol: detection and quantification of integrated HIV Psi sequence. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.bp2l6ok9klqe\/v1 (2026).","DOI":"10.17504\/protocols.io.bp2l6ok9klqe\/v1"},{"key":"1194_CR77","doi-asserted-by":"publisher","unstructured":"Song, H. et al. Single-Cell GEX and VDJ (TCR) sequencing protocol: library preparation, sequencing, and analysis. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.yxmvmdoebv3p\/v1 (2026).","DOI":"10.17504\/protocols.io.yxmvmdoebv3p\/v1"},{"key":"1194_CR78","doi-asserted-by":"publisher","unstructured":"Gill, G. et al. Visium HD spatial gene expression protocol: library preparation, sequencing, and analysis. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.bp2l6okd1lqe\/v1 (2026).","DOI":"10.17504\/protocols.io.bp2l6okd1lqe\/v1"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01194-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01194-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01194-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:08:17Z","timestamp":1787321297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01194-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":78,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1194"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01194-3","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published, Mona Shafey, A. Sorana Morrissy and Douglas J. Mahoney were listed as having equally contributed with Zackariah Breckenridge, Hyojin Song, Gurveer S. Gill and Taye L. Louie. This has now been corrected so that Mona Shafey, A. Sorana Morrissy and Douglas J. Mahoney are listed as having equally supervised the work. This correction has been made to the HTML and PDF versions of the article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.J.M. and F.J.Z. are inventors on the patent application ANTI-GPNMB CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE (US provisional patent application 63\/423,405, January 2023; PCT\/IB2023\/061240, November 2023). The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}